Form 4 for AVTR Avantor, Inc.
Accepted 2024-02-27 00:00:00 ET · period of report 2024-02-23 · accession 0001722482-24-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-27 | 2024-02-23 | AVTR | Gourdier Benoit | EVP, Biopharma Production | A - Grant | $0.00 | +25.7K | 42.5K | +153% | $0 |
| D | 2024-02-27 | 2024-02-23 | AVTR | Gourdier Benoit | EVP, Biopharma Production | A - Grant | $0.00 | +62.8K | 62.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-23 | A | A | 25,667 | $0.00 | 42,453 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2024-02-23 | A | A | 62,753 | $0.00 | 62,753 | D | $24.35 · — to 2034-02-23 | 62,753 Common Stock | (F2) Reflects a grant of stock options that vest in three equal annual installments beginning on February, 23, 2025. |